Summary Sublines of the human small-cell lung carcinoma (SCLC) cell line GLC4 with acquired resistance to teniposide, amsacrine and mitoxantrone (GLC4/VM20 ,, GLC4/AM3, and GLC4/MIT60 ,, respectively) were derived to study the contribution of DNA topoisomerase Ila and -,B (Topolla and -,B) to resistance for Topolltargeting drugs. The cell lines did not overexpress P-glycoprotein or the multidrug resistance-associated protein but were cross-resistant to other TopoIl drugs. GLC4/VM20x showed a major decrease in Topolla protein (54%; for all assays presented in this paper the GLC4 level was defined to be 100%) without reduction in TopoII,B protein; GLC4/AM3X showed only a major decrease in TopoII,B protein (to 18%) and not in Topolla.
The interest in type II DNA topoisomerases (Topolla and -,B) increased after it was shown that these isozymes are targets for certain drugs used in cancer therapy (Liu, 1989) . TopoIl drugs stabilise the covalent binding of Topoll to DNA during the catalytic cycle of the enzyme. The presence of this so-called cleavable complex leads to DNA damage by interactions with molecules that move along the DNA strand (Howard et al., 1994) , and ultimately to cell death by an unknown mechanism. There is a causal relationship between drug-induced topoisomerase IT-mediated DNA breaks and cytotoxicity (Covey et al., 1988) . Although Topollx displays similarities at the sequence level with TopoII,B (Austin et al., 1993) , differences can be found in expression pattern during the cell cycle (Woessner et al., 1991; Kimura et al., 1994) , chromosomal localisation of the genes encoding both enzymes (Tan et al., 1992) , distribution of the proteins in the nucleus (Zini et al., 1994) and the optimal potassium chloride concentration for catalytic activity (Drake et al., 1989) . It was suggested that Topollcx is more sensitive for Topoll-targeting drugs than TopoII,B (Drake et al., 1989) and that Topollo-mediated strand breaks contribute most to cytotoxicity (Woessner et al., 1990) .
A major problem involved in anti-cancer treatment with Topo inhibitors is the emergency of drug resistance. This can be mediated by overexpression of drug efflux pumps such as P-glycoprotein (P-gp) and the multidrug resistance-associated protein (MRP) (Ling, 1992; Cole et al., 1992; Zaman et al., 1994) . Overexpression of these pumps results in increased efflux of drugs from the cell before they reach their target (Topoll) in the cell nucleus. However, changes in Topoll level can also induce resistance.
Topoll-related drug resistance results from a decrease in cleavable complex formation in the nucleus, which will lead Correspondence: EGE de Vries Received 19 April 1996; revised 10 July 1996; accepted 16 July 1996 to less DNA damage and less cell death. Less cleavable complex formation can be due to a decrease in TopoIl protein, Topoll point mutations changing drug or ATP binding or the binding characteristics of Topoll to DNA, changed cellular localisation of Topoll (Feldhoff et al., 1994) or an altered phosphorylation status of the enzyme (reviewed in Beck et al., 1994b; Pommier et al., 1994) . Previously, we have described a cell line panel derived from the small-cell lung carcinoma (SCLC) cell line GLC4, with increasing doxorubicin resistance (Versantvoort et al., 1995) . In this panel, drug accumulation defects and MRP expression levels increased with increasing resistance while Pgp was not involved. In addition, Topoloc protein levels decreased with increasing resistance, which could be related to decreased Topolla gene copy numbers as was found by fluorescence in situ hybridisation (FISH; Withoff et al., 1996) .
To analyse further the importance of Topoll in Topoll drug resistance, the GLC4 cell line was made resistant in vitro for teniposide (VM26), amsacrine (mAMSA) and mitoxantrone. These three compounds are all known to inhibit Topoll. The cell lines were characterised for cross-resistance, P-gp and MRP expression, drug accumulation level and Topollo and -/ characteristics such as gene copy number, mRNA expression, protein content and Topoll activity.
Materials and methods Cell lines
GLC4 is a SCLC cell line isolated from a pleural effusion. Its doxorubicin-resistant subline GLC4/ADR350o (resistance factor to the drug of interest in subscript) was characterised and described previously (Versantvoort et al., 1995; Zijlstra et al., 1987; De Jong et al., 1990 Muller et al., 1994; Withoffet al., 1994 
Results

Cell lines
The parental cell line GLC4 grows partly floating/partly attached, the doxorubicin-and the VM26-resistant sublines strongly attached to the culture flask and the mAMSA-and the mitoxantrone-resistant sublines floating in the medium. The doubling times of GLC4/VM20 , GLC4/AM3x and GLC4/MIT60X were, respectively, 1.3, 1.1 and 1.0 times increased when compared with the doubling time of the parent cell line GLC4 (16.9 h). approximately 5% lower and GLC4/VM20x cell volume was 10% lower than GLC4; GLC4/AM3x had the same cell volume as GLC4.)
Protein expression of P-gp and MRP and TopoIIcx and -/3 mRNA and protein levels Immunohistochemistry showed that P-gp was not overexpressed in any of the cell lines (results not shown). Figure   I shows a MRP Western blot. Only the doxorubicinresistant subline displayed overexpression of MRP protein as reported previously (Versantvoort et al., 1995; Muller et al., 1994) . The other resistant sublines displayed MRP protein levels lower than the parental cell line, GLC4. Representative Topoll cx and -/3 Northern and Western blotting results are also shown in Figure 1 . In Table II , the Topoll expression data are summarised and expressed as a percentage of the GLC4 value. Topollo and -,B mRNA levels seem to be regulated differentially. In GLC4/ADR350 x, Topollcx and -/ mRNA levels decrease similarly compared with the levels in GLC4; in the other cell lines, this is not the case. TopolloI levels are the lowest in GLC4/VM20. and GLC4/MIT60 , TopoII,B levels decrease especially in GLC4/ AM3X and GLC4/MIT60,. The protein levels correlate with the mRNA levels for TopollI and TopoII3 (see Figure 2a and b). aTopollft protein levels were too low to be quantitated (ND, = not dectable).
TopoII activity
The results of the Topoll activity assay are summarised in Table II. In the four Topoll drug-resistant cell lines, there was a correlation between Topollo mRNA levels and overall Topoll activity (see Figure 2c) . No correlation was observed between TopoII,B mRNA levels and Topoll activity ( Figure  2d ). The resistance levels of the cell lines for the various drugs (Table I) were correlated with Topollx and -,B mRNA levels (Table II) . For the drugs mAMSA (r =-0.87, P = 0.03), VM26 (r = -0.90, P = 0.02), mitoxantrone (r =-0.90, P= 0.02) and fostriecin (r= 0.80, P= 0.05), a relationship with Topolcx mRNA levels was observed.
Discussion
Several reports have been published correlating Topoll levels with drug sensitivity (Deffie et al., 1989; Fry et al., 1991) . Direct evidence for a correlation between drug sensitivity and Topoll expression came from transfection studies using eukaryotic (including human) TopoII-expression vectors (Nitiss et al., 1992; Asano et al., 1995; McPherson et al., 1995) . In a doxorubicin-resistant SCLC cell line (GLC4/ ADR350 x ), we have described that doxorubicin resistance was due to multifactorial changes (Versantvoort et al., 1995; Zijlstra et al., 1987; De Jong et al., 1990 Meijer et al., 1987) . Relevant resistance-associated features of GLC4/ADR350, are its cross-resistance to a wide variety of drugs, drug accumulation defects, overexpression of MRP and down-regulation of Topollcx and -,B. In order to study the importance of TopoIl in resistance to Topoll drugs, we developed three cell lines with resistance for other Topoll-targeting drugs from the same parental cell line, GLC4.
From the cross-resistance factors presented in Table I , it was concluded that all the resistant sublines showed crossresistance for the 'classical' Topoll inhibitors (doxorubicin, VM26, mAMSA and mitoxantrone). Although P-gp and MRP may be involved in resistance for VM26 and mitoxantrone, no overexpression of these proteins was observed. Also, no drug accumulation defects were found in GLC4/VM20, and GLC4/AM3 ,. This indicates that Topoll isoenzyme decreases alone can determine resistance. It was of interest to find that GLC4/MIT.,, shows a mitoxantrone accumulation defect. Possible explanations for the mitoxantrone accumulation defect in GLC4/MIT60x could be the enhanced activation (phosphorylation) of the MRP protein (Ma et al., 1995) , a changed membrane structure of the cell, altered localisation of mitoxantrone in the cell by compartmentalisation in vesicles giving rise to an altered fluorescence signal or overexpression or activation of a yet unknown drug efflux pump. The possibility that changes in intracellular compartmentalisation may also play a role in the resistance of these cell lines was not investigated.
In a recent review, several Topoll drug-resistant cell lines were listed (Beck et al., 1994b) . The Topoll-related resistance mechanisms, which were also reviewed, were almost always found to involve the Topolloc isoenzyme. However, the authors suggested that the role of TopoII,B might also be of importance. Indeed, we observed that in ovarian tumours TopoII mRNA levels correlated better with overall Topoll activity than TopoIla mRNA levels ( Van der Zee et al., 1995) . Others showed that in lung cancer cell lines no clear association existed between TopollI level, Topoll activity and sensitivity to doxorubicin and etoposide (Yamazaki et al., 1995) . Topollo and TopoII,B levels vary in different tumour types (D'Andrea et al., 1995) . Therefore, the Topolla/TopoIIlB ratio may be of importance in drug resistance. The possible relevance of TopoII,l was also shown by data obtained with cDNA PCR for mononuclear cells isolated from chronic lymphocytic leukaemia patients, in which Topollx mRNA levels were often low or even undetectable whereas TopoII,B levels were relatively high as determined by PCR (Beck et al., 1994a ).
In our cell lines, Topolla and -# levels decreased differentially which may be owing to the use of drugs from different drug classes. Topollcx was down-regulated considerably in GLC4/ADR350 x, GLC4/VM20, and in GLC4/MIT60x.
TopoIIlf was down-regulated especially in the GLC4/ ADR350s,, GLC4/AM3. and GLC4/MIT60 ,. The downregulation of Topollo mRNA may be caused by gene dosage effects, as the majority of the cells in the resistant sublines containing decreased Topollo mRNA levels have lost one TopoIIal gene copy (from three to two). We postulate that in the parental cell ine, GLC4, a small population of cells is present containing two Topolla gene copy numbers that are selected during resistance development. This selection mechanism was previously demonstrated in a cell line panel with increasing doxorubicin resistance levels (Withoff et al., 1996) . Southern blot analysis of the Topolla gene using genomic DNA restricted with various restriction enzymes had already shown no restriction pattern differences between the cell lines, indicating that the Topolla gene was not rearranged in the resistant cell lines (results not shown).
GLC4/VM20x and GLC4/AM3x especially, may be used for the study of the contribution of down-regulation of Topolla and TopoIIl IN in resistance, as these cell lines do not show expression of any of the other resistance mechanisms which were investigated. Therefore, the cross-resistance pattern in these cell lines may result from a decrease in Topolla and/or (Feldhoff et al., 1994) . Taken together, these results suggest that Topollrelated mitoxantrone resistance may be mediated by TopoIIlf.
On the other hand, it was found that preincubation of human leukaemia cells with mitoxantrone did not protect TopoII,B from degradation, while VM26 did (Danks et al., 1994) . More research is needed to clarify the relationship between mitoxantrone and TopoII,B. It is possible that Topollo has taken over functions that are normally performed by TopoII3.
Immune fluorescence studies using Topolla-specific monoclonals might reveal whether Topolla is located in nucleoli, where TopoII,B performs its function (Zini et al., 1994) .
Although the possibility exists that other (unknown) resistance mechanisms may also be involved in resistance development of the presented cell lines, we performed a Spearman rank correlation test to see whether Topoll levels predict the resistance (sensitivity) pattern of the cell line panel. Significant correlations were found between Topolla mRNA levels and resistance to mAMSA, VM26, mitoxantrone and fostriecin (see Results section). Decreased Topolla mRNA levels seem to predict mAMSA, VM26 and mitoxantrone resistance. This is in agreement with the hypothesis that the TopolIx enzyme is more sensitive for Topoll drugs than Topollfl. It is therefore remarkable that GLC4/AM3x has not decreased its Topollx level but its Topollf level, as this cell line was also derived from GLC4. Furthermore, a significant correlation was found between decreased Topollx mRNA levels and fostriecin sensitivity. Fostriecin is a drug which inhibits Topoll activity and does not induce cleavable complexes like other drugs used in this study (Boritzki et al., 1988 The results obtained for the panel of cell lines described here suggests that further studies are required on the relation between mitoxantrone and known efflux systems and on the influence of TopoIIfl in resistance and sensitivity to some drugs, usually considered to be associated with TopolI. The cell line panel which is described in this paper may contribute significantly to Topoll research as it provides resistant sublines of one parental cell line (so they have a relatively similar genetic background) with different Topoll isoenzyme expression patterns. One cell line displays only a TopoIlc decrease (GLC4/VM20 x), one only a TopolIl decrease (GLC4/AM3 x), one a decrease in both isozymes (GLC4/ADR350 x) and one displays a decrease in Topollcx and has undetectable TopoII protein levels (GLC4/MIT60 x). Abbreviations B, 0.5% block reagent; CSPD, disodium 3-(4-methoxyspiro{ 1,2-dioxitane-3,2'-(5'-chloro)tricyclo[3.3. 1.1 3,7decan}-4-yl)phenyl phosphate; FISH, fluorescence in situ hybridisation; FITC, fluorescein isothiocyanate; HPLC, high performance liquid chromatography; mAMSA, amsacrine; MRP, multidrug resistance-associated protein; PBS, phosphate-buffered saline (0.58 M disodium hydrogen phosphate, 0.17 M sodium dihydrogen phosphate and 0.68 M sodium chloride); P-gp, P-glycoprotein; PI, propidium iodide; SCLC, small-cell lung carcinoma; SDS, sodium dodecyl sulphate; SSC, 0.15 M sodium chloride, 0.015 M sodium citrate, pH 7.0; T, 0.05% Tween 20; Topolla and -,B, DNA topoisomerase Ilx and /1; VM26, teniposide.
